All companies
Visit website
Rejuve.Bio
OperatingRejuve Biotech Inc.
Healthcare · Biotech · Founded 2022
Aims to revolutionize the field of longevity treatments and extend hum health span
Post-money valuation ⓘ
$40.3M
As of Dec 2024 · from Rejuve.Bio Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$288,551
Across 1 round since 2024
Latest share price
$8.33
Rejuve.Bio Common Stock 1 offering price
Financials
FY2021–FY2025 · from SEC filings · hover any figure for its source$0
2021
$0
2022
$0
2023
$0
−$14K
2024
$0
−$58K
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
$0
Net income
$0
$0
$0
-$13,513
-$57,800
Taxes paid
$0
$0
$0
$0
$0
Balance sheet
Cash
$0
$0
$0
$257,811
$136,092
Accounts receivable
$0
$0
$0
$0
$0
Total assets
$0
$0
$0
$257,811
$136,092
Short-term debt
$0
$0
$0
$0
$0
Long-term debt
$0
$0
$0
$0
$0
Total liabilities
$0
$0
$0
$0
$0
Other
Headcount
—
0
—
6
6
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$40.3M
post-money
Rejuve.Bio Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $288.6K / $5MPost-money $40.3M
Reg CF annual-report compliance
Possibly delinquent
Filed 2 of 3 annual reports (FY2023–FY2025)
Missing: 2023
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 9 filings on EDGARSource: ManualCIK 0001994911Share price $8.33
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.